Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

被引：0
|
作者：
Cho, B. C. [1 ]
Cheng, Y. [2 ]
Zhou, C. [3 ]
Ohe, Y. [4 ]
Imamura, F. [5 ]
Lin, M-C. [6 ]
Majem, M. [7 ]
Shah, R. [8 ]
Rukazenkov, Y. [9 ]
Todd, A. [10 ]
Markovets, A. [11 ]
Barrett, C. [11 ]
Chmielecki, J. [11 ]
Gray, J. E. [12 ]
Ramalingam, S. S. [13 ]
机构：
[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol,Dept Internal Med, Seoul, South Korea
[2] Jilin Prov Canc Hosp, Dept Oncol, Changchun, Jilin, Peoples R China
[3] Tongji Univ, Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
[4] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[5] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[6] Kaohsiung Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan
[7] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[8] Maidstone & Tunbridge Wells NHS Trust, Maidstone Hosp, Kent Oncol Ctr, Maidstone, Kent, England
[9] AstraZeneca, GMED Oncol, Global Med Dev, Cambridge, England
[10] AstraZeneca, Biometr & Informat Sci, Cambridge, England
[11] AstraZeneca, IMED Biotech Unit, Translat Sci, Waltham, ME USA
[12] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA8
引用
收藏
页码：177 / 177
页数：1
相关论文
共 50 条
  • [31] Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC: FLAURA China study overall survival (OS)
    Cheng, Y.
    He, Y.
    Li, W.
    Zhang, H-L.
    Zhou, Q.
    Wang, B.
    Liu, C.
    Walding, A.
    Saggese, M.
    Huang, X.
    Liu, Y.
    Su, R.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S838 - S839
  • [32] Drug Sensitivity and Allele-specificity of First-line Osimertinib Resistance <it>EGFR</it> Mutations
    Starrett, Jacqueline
    Guernet, Alexis
    Cuomo, Maria
    Poels, Kamrine
    van Rosenburgh, Iris
    Nagelberg, Amy
    Farnsworth, Dylan
    Price, Kristin
    Khan, Hina
    Ashtekar, Kumar
    Gaefele, Mmaserame
    Ayeni, Deborah
    Stewart, Tyler
    Kuhlmann, Alexandra
    Kaech, Susan
    Unni, Arun
    Homer, Robert
    Lockwood, William
    Michor, Franziska
    Goldberg, Sarah
    Lemmon, Mark
    Smith, Paul
    Cross, Darren
    Politi, Katerina
    FASEB JOURNAL, 2020, 34
  • [33] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
    Smit, E. F.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
  • [34] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
    Planchard, D.
    Janne, P. A.
    Cheng, Y.
    Lee, C. K.
    Laktionov, K.
    Yang, T-Y.
    Yu, Y.
    Kato, T.
    Jiang, L.
    Chewaskulyong, B.
    Geater, S. Lucien
    Maurel, J-M.
    Rojas, C.
    Havel, L.
    Shepherd, F. A.
    Tanaka, K.
    Ghiorghiu, D.
    Monterroso, E. Armenteros
    Huang, X.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1668 - S1668
  • [35] Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies
    Campo, Meghan
    Gerber, David
    Gainor, Justin F.
    Heist, Rebecca S.
    Temel, Jennifer S.
    Shaw, Alice T.
    Fidias, Panos
    Muzikansky, Alona
    Engelman, Jeffrey A.
    Sequist, Lecia V.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : 2022 - 2026
  • [36] Osimertinib (OSI) vs Standard of Care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Bischoff, H. G.
    Rueckert, A.
    Reinmuth, N.
    Grohe, C.
    Bohnet, S.
    zum Bueschenfelde, C. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 187 - 187
  • [37] Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials
    Twelves, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S15 - S20
  • [38] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
    Planchard, D.
    Janne, P. A.
    Cheng, Y.
    Lee, C. K.
    Laktionov, K.
    Yang, T. Y.
    Yu, Y.
    Kato, T.
    Jiang, L.
    Chewaskulyong, B.
    Geater, S. Lucien
    Maurel, J. M.
    Rojas, C.
    Havel, L.
    Shepherd, F. A.
    Tanaka, K.
    Ghiorghiu, D.
    Monterroso, E. Armenteros
    Huang, X.
    Yang, J. C. H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1311 - S1312
  • [39] Mechanisms of action and resistance to INH, a first-line antituberculous drug
    Brossier, F.
    JOURNAL DES ANTI-INFECTIEUX, 2011, 13 (04) : 217 - 227
  • [40] Patients with uncommon EGFR mutations also benefit from first-line osimertinib
    Diana Romero
    Nature Reviews Clinical Oncology, 2024, 21 : 84 - 84
12345